Papers

Jul, 2004

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug resistance phenotype in multiple myeloma

AMERICAN JOURNAL OF PATHOLOGY
  • J Inoue
  • ,
  • T Otsuki
  • ,
  • A Hirasawa
  • ,
  • Imoto, I
  • ,
  • Y Matsuo
  • ,
  • S Shimizu
  • ,
  • M Taniwaki
  • ,
  • J Inazawa

Volume
165
Number
1
First page
71
Last page
81
Language
English
Publishing type
Research paper (scientific journal)
Publisher
AMER SOC INVESTIGATIVE PATHOLOGY, INC

We investigated DNA copy number aberrations in 37 cell lines derived from multiple myelomas (MMs) using comparative genomic hybridization, and 11 (29.7%) showed high-level gain indicative of gene amplification at 1q12-q22. A corresponding transcriptional mapping using oligonucleotide arrays extracted three up-regulated genes (IRTA2, PDZK1, and S100A6) within the smallest region of overlapping in amplifications. Among them PDZK1 showed amplification and consequent overexpression in the MM cell lines. Amplification of PDZK1 was observed in primary cases of MM as well. MM cell lines with amplification of PDZK1 exhibited the resistance to melphalan-, cis-platin-, and vincristin-induced cell death compared with MM cell lines without its amplifications. Furthermore, down-regulation of PDZK1 with an anti-sense oligonucleotide sensitized a cell line KMS-11 to melphalan, cis-platin, and vincristin. Taken together, our results indicate that PDZK1 is likely to be one of targets for 1q12-q22 amplification in MM and may be associated with the malignant phenotype, including drug resistance, in this type of tumor.

Link information
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000222216000007&DestApp=WOS_CPL
ID information
  • ISSN : 0002-9440
  • Web of Science ID : WOS:000222216000007

Export
BibTeX RIS